Updated Results of a Phase II Study: Neoadjuvant Inetetamab Combined with Pertuzumab, Paclitaxel and Carboplatin for Locally Advanced HER2-Positive Breast Cancer

被引：0
|
作者：
Chai, Yue
Liu, Jiaxuan
Jiang, Mingxia
He, Maiyue
Wang, Xin
Wang, Yipeng
Yang, Xue
Wang, Jing
Xu, Binghe
Li, Qiao
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-18-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-18-12
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience
    Tiwari, A.
    Gogia, A.
    Deo, S. V. S.
    Shukla, N. K.
    Mathur, S.
    Sharma, D. N.
    INDIAN JOURNAL OF CANCER, 2017, 54 (01) : 343 - 346
  • [32] Phase II study of bavituximab plus paclitaxel and carboplatin in locally advanced or metastatic breast cancer: Interim results
    Jain, M.
    Raizada, N.
    Kuttan, R.
    Shan, J.
    Digumarti, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.
    Lavasani, Sayeh Moazami
    Yost, Susan Elaine
    Frankel, Paul Henry
    Ruel, Christopher
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Kruper, Laura
    Tumyan, Lusine
    Schmolze, Dan
    Menghi, Francesca
    Liu, Edison T.
    Yeon, Christina Haeyoung
    Yuan, Yuan
    Waisman, James Ross
    Somlo, George
    Mortimer, Joanne E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Neoadjuvant intetamab in combination with standard chemotherapy for locally advanced HER2-positive breast cancer
    Jiang, M.
    Chai, Y.
    Liu, J.
    He, M.
    Zhang, M.
    Zhou, S.
    Xu, B.
    Li, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S353 - S353
  • [35] Phase II study of neoadjuvant weekly paclitaxel and carboplatin with lapatinib in HER2+breast cancer.
    Wong, Andrea Li Ann
    Tan, Sing Huang
    Soh, I. Peng Thomas
    Tan, Chee Seng
    Lim, Yi Wan
    Pang, Angela
    Ho, Jingshan
    Ow, Samuel Guan Wei
    Sundar, Raghav
    Pang, Mei-Yan
    Chan, Ching-Wan
    Buhari, Shaik Ahmad
    Hartman, Mikael
    Iau, Philip
    Tang, Anthony
    Wong, Nan-Soon
    Yap, Yoon Sim
    Khoo, Bee-Luan
    Thiery, Jean Paul
    Lee, Soo-Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Safety data from a phase II study of neoadjuvant bevacizumab and trastuzumab administered with albumin bound paclitaxel (nab paclitaxel) and carboplatin in HER2+locally advanced breast cancer
    Yardley, D.
    Raefsky, E.
    Castillo, R.
    Lahiry, A.
    Thompson, D.
    Hanson, S.
    Meng, C.
    Knauer, D.
    Trieu, V.
    Desai, N.
    EJC SUPPLEMENTS, 2008, 6 (07): : 117 - 117
  • [37] Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
    Vieira, Claudia
    Borges, Andreia
    Pereira, Filipa F.
    Antunes, Pedro
    Redondo, Patricia
    Antunes, Luis
    Lopes, Jose M.
    Goncalves, Francisco R.
    Borges, Marina
    Bento, Maria J.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 1 - 9
  • [38] Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada
    Attard, C. L.
    Pepper, A. N.
    Brown, S. T.
    Thompson, M. F.
    Thuresson, P. -O.
    Yunger, S.
    Dent, S.
    Paterson, A. H.
    Wells, G. A.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (03) : 173 - 188
  • [39] A two-cohort, phase II, cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with HER2-positive, locally advanced, inflammatory, or early breast cancer
    Swain, Sandra M.
    Ewer, Michael S.
    Douthwaite, Hannah
    Szado, Tania
    Waldron-Lynch, Maeve
    Dang, Chau
    CANCER RESEARCH, 2015, 75
  • [40] Pertuzumab study for HER2-positive non-metastatic breast cancer in the neoadjuvant setting in Australia
    Lok, Sheau Wen
    De Boer, Richard
    Baron-Hay, Sallt
    Button, Peter
    Devitt, Bianca
    Forster, Benjamin
    Fox, Peter
    Harold, Michael
    Ketheeswaran, Sahisha
    Kichenadasse, Ganessan
    Kiely, Belinda E.
    Marx, Gavin
    Nott, Louise
    Pellegrini, Laura
    Tafreshi, Ali
    Gibbs, Peter
    CANCER RESEARCH, 2022, 82 (04)
12345